Biogen offering Aduhelm free-to-charge to some healthcare providers

Biogen, Inc., the maker of the controversial and expensive new Alzheimer’s drug, is offering the medication free of charge for some patients. Aduhelm, a monthly infusion, was approved by the U.S. Food and Drug Administration in June; however, Medicare has not approved reimbursement for the medication.   So, Biogen has started to provide the drug to providers free-to-charge. Read the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org